Market Overview

UPDATE: Sterne Agee Reiterates On Salix Pharmaceuticals Ahead Of FDA Panel Vote

Share:
Related SLXP
Benzinga's Volume Movers
US Stock Futures Edge Lower Ahead Of ADP Report

In a report published Thursday, Sterne Agee analyst Shibani Malhotra reiterated a Buy rating on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), and raised the price target from $126.00 to $130.00.

In the report, Sterne Agee noted, “We reiterate our Buy thesis on SLXP in front of the FDA panel vote, expected later this afternoon, regarding the use of Relistor as a possible treatment for opioid-induced constipation. A path to development can add around $6 to our fair value of $130 for SLXP, while a negative outcome should have little impact given the minimal expectations going into this event. We are more focused on the data from TARGET III for Xifaxan in IBS-D (early July) as a meaningful positive catalyst for the stock.”

Salix Pharmaceuticals Ltd. closed on Wednesday at $113.42.

Latest Ratings for SLXP

DateFirmActionFromTo
Mar 2015JefferiesDowngradesBuyHold
Feb 2015UBSDowngradesBuyNeutral
Feb 2015Cantor FitzgeraldDowngradesBuyHold

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings

Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Price Target Analyst Ratings

 

Related Articles (SLXP)

Get Benzinga's Newsletters